Maa: Kanada
Kieli: englanti
Lähde: Health Canada
ETOMIDATE
MARCAN PHARMACEUTICALS INC
N01AX07
ETOMIDATE
2MG
SOLUTION
ETOMIDATE 2MG
INTRAVENOUS
15G/50G
Prescription
Active ingredient group (AIG) number: 0162234001; AHFS:
APPROVED
2022-03-02
_Etomidate Injection USP _ _Page 1 of 28_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ETOMIDATE INJECTION USP Solution, 2 mg/mL, Intravenous USP General Anesthetic Marcan Pharmaceuticals Inc. Date of Initial Authorization: 2 Gurdwara Road, Suite #112 FEB 18, 2022 Ottawa, ON K2E 1A2 Submission Control Number: 254122 _Etomidate Injection USP _ _Page 2 of 28_ RECENT MAJOR LABEL CHANGES Not applicable. TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ...................................................................................................... 2 TABLE OF CONTENTS ........................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................... 3 1. INDICATIONS ................................................................................................................................... 3 1.1 Pediatrics .................................................................................................................................... 3 1.2 Geriatrics .................................................................................................................................... 3 2 CONTRAINDICATIONS .................................................................................................................... 3 3 DOSAGE AND ADMINISTRATION ................................................................................................... 4 3.1 Dosing Considerations ................................................................................................................ 4 3.2 Recommended Dose and Dosage Adjustment ............................................................................ 4 3.3 Administration ....................................................................................................................... Lue koko asiakirja